US Patent

US8193196 — Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations

Composition of Matter · Assigned to Alfa Wasserman SpA · Expires 2027-09-02 · 1y remaining

Vulnerability score 22/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects crystalline polymorphous forms of rifaximin, specifically rifaximin δ and rifaximin ε, and methods for producing them.

USPTO Abstract

Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1707 — Xifaxan

Patent Metadata

Patent number
US8193196
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-09-02
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Alfa Wasserman SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.